{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=13", "query": { "condition": "Hepatitis C Virus Infection", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 901, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:45:48.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01125189", "title": "Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "peg-interferon alfa-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 558, "start_date": "2010-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 33, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125189" }, { "nct_id": "NCT02103699", "title": "A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "No intervention", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2014-02", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-02-22", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02103699" }, { "nct_id": "NCT03627299", "title": "Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Renal Disease", "Hepatitis C" ], "interventions": [ { "name": "300mg glecaprevir/pibrentasivir 120mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-25", "completion_date": "2021-09-20", "has_results": true, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627299" }, { "nct_id": "NCT01805882", "title": "Combination Therapy for Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ledipasvir", "type": "DRUG" }, { "name": "GS-9669", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2013-01", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01805882" }, { "nct_id": "NCT02304159", "title": "Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Cirrhosis" ], "interventions": [ { "name": "daclatasvir", "type": "DRUG" }, { "name": "Sofosbuvir, Sovaldi", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarek I. Hassanein, M.D., FACP, FAG, AGAF", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2015-01", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-04-24", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 1, "location_summary": "Coronado, California", "locations": [ { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304159" }, { "nct_id": "NCT07406490", "title": "Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus (HCV)", "Hepatitis C Virus (HCV) Infection", "HIV (Human Immunodeficiency Virus)" ], "interventions": [ { "name": "Physician-Initiated Screening (Conventional Screening)", "type": "OTHER" }, { "name": "FOCUS (Universal Screening)", "type": "OTHER" }, { "name": "HepC-EnD (Targeted Screening)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 6466, "start_date": "2026-07-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 3, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07406490" }, { "nct_id": "NCT03126370", "title": "Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "HIV Coinfection" ], "interventions": [ { "name": "TDF with a boosted protease inhibitor", "type": "DRUG" }, { "name": "TAF with a boosted protease inhibitor", "type": "DRUG" }, { "name": "TAF with a boosted protease inhibitor and LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2018-01-08", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126370" }, { "nct_id": "NCT04268173", "title": "Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Drug Use Disorders", "Hepatitis C", "Harm Reduction", "Opioid-use Disorder" ], "interventions": [ { "name": "Community-Based, Client-Centered Prevention Home", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2020-03-12", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 6, "location_summary": "Appleton, Wisconsin • Eau Claire, Wisconsin • Green Bay, Wisconsin + 3 more", "locations": [ { "city": "Appleton", "state": "Wisconsin" }, { "city": "Eau Claire", "state": "Wisconsin" }, { "city": "Green Bay", "state": "Wisconsin" }, { "city": "La Crosse", "state": "Wisconsin" }, { "city": "Schofield", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268173" }, { "nct_id": "NCT00851890", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus Infection" ], "interventions": [ { "name": "ABT-333", "type": "DRUG" }, { "name": "Placebo for ABT-333", "type": "OTHER" }, { "name": "Pegylated interferon", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2009-03", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 7, "location_summary": "Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00851890" }, { "nct_id": "NCT00449124", "title": "TG4040 in Patients With Chronic HCV", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TG4040", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-10-14T11:45:48.568Z", "location_count": 2, "location_summary": "St Louis, Missouri • Cincinnati, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00449124" } ] }